Allegria Therapeutics

Developer of therapeutics for allergy and inflammatory diseases

placeBasel, Basel Stadt, Switzerland calendar_todayFounded 2023 language allegriatx.com

Social engagement

Social engagement: 692 social following, 6 posts in the last 12 months — below the industry typical range.

Investor mix

4 investors on record; lead investors include Forty51 Ventures, ALK-Abello.

Investor typeCountShare
Venture capital250%
Other / undisclosed250%
Coming soon